Press release
Versatile Thermoplastic Biomaterial Brings Exceptional Performance in New DOMINO Spinal Fusion Cages

ALPHARETTA, Ga., July 25, 2013 – Sintea Plustek S.r.l., based in Milan, Italy, a leading supplier of minimally invasive spinal implants and delivery systems, has launched the new DOMINO cervical fusion cage implant made of Sintea Plustek selected Zeniva® PEEK – part of Solvay’s line of Solviva® Biomaterials – because of its modulus of elasticity which is very close to that of bone, thus allowing better load transfer. The thermoplastic biomaterial also has radiolucent properties which permit x-ray procedures and meets the requirements of ASTM F2026-12 for surgical implant applications, according to Laura Dell’Orto, technical marketing manager for Sintea Plustek.

The DOMINO cervical plate-cage system allows cervical interbody fusion and disc height restoration by an anterior fixation. The implant system consists of an intersomatic cage made of 16-mm diam. machined Zeniva® PEEK rod which is integrated with an anterior fixation plate made of titanium alloy. The implant is available in three sizes, which allows for perfect adaptation to the patient’s anatomy. The cage has a convex shape on its superior face to fit perfectly in the intervertebral space and it is centrally opened to allow bone graft insertion which promotes fusion. The primary stability of the system, guaranteed by the anterior plate, is enhanced by the presence of notches on the superior and inferior surfaces.

Zeniva® PEEK offers numerous advantages over metals such as titanium for spinal implants. The material offers many important benefits including biocompatibility, chemical inertness, and a modulus of elasticity that is close to that of bone. Based on biocompatibility testing, Zeniva® PEEK demonstrates no evidence of cytotoxicity, sensitization, irritation, or acute systemic toxicity. It also boasts high strength and stiffness. Sintea Plustek uses Zeniva® PEEK rod stock and performs high-precision machining to produce a full range of sizes.

The manufacturing site for Zeniva® PEEK and other Solviva® Biomaterials in Alpharetta, Ga., is ISO 13485 registered and the relevant aspects of current Good Manufacturing Practices are also applied. Solvay’s biomaterial manufacturing processes are carefully validated and enhanced controls provide product traceability. In addition, all materials are tested in an ISO 17025 accredited lab.

Sintea Plustek plans to sell the cervical fusion cage system globally and has already submitted technical documentation to regulatory bodies in various countries outside of Europe.

20130725-Sintea-Plustek


In addition to Zeniva® PEEK, Solvay’s Solviva® Biomaterials line includes Proniva® self-reinforced polyphenylene (SRP), one of the world’s stiffest and strongest unreinforced thermoplastics which offers exceptional biocompatibility and hardness; Veriva® polyphenylsulfone (PPSU), which provides unsurpassed toughness combined with transparency and excellent biocompatibility; and Eviva® polysulfone (PSU), which offers practical toughness in a strong, transparent polymer.

About Sintea Plustek
Sintea Plustek S.r.l., a leading supplier of minimally invasive spinal implants and delivery systems, plays an important role in the orthopedic and neurosurgical markets. The company was created from the merger of two companies: Sintea Biotech spa and Plustek srl. Sintea Biotech specialized in the spine market, offering a wide range of innovative products for the international market. Plustek brings broad experience as a pioneer in the Italian orthopedic market. The combination of the two companies has resulted in great synergies that deliver unique high-quality products for the medical market. Sintea Plustek has offices and production facilities in Milan, Italy, with a subsidiary in Miami, Fla., USA. All medical devices have obtained the CE mark and many have been proven and met approval by the U.S. Food & Drug Administration (FDA). For more information, visitwww.sinteaplustek.com.

About Solvay Specialty Polymers 
Solvay Specialty Polymers is a leading global supplier of high-performance thermoplastics for implantable and non-implantable medical devices. The company has expanded its focus on the healthcare industry to meet the growing needs of its global customers. Solvay is building on its 20-year history as a key material supplier in the healthcare field, devoting considerable new resources to help customers be more efficient and cut costs. Metal-to-plastic replacement remains a key focus for manufacturers, but increased cost pressures pose a new challenge as the market continues to grow at a double-digit pace. Solvay also continues to devote considerable research and development activities to polymer technology and commercialization of new and unique material options for medical OEMs and processors.

Solvay Specialty Polymers manufactures over 1500 products across 35 brands of high-performance polymers – fluoropolymers, fluoroelastomers, fluorinated fluids, semi-aromatic polyamides, sulfone polymers, aromatic ultra polymers, high-barrier polymers and cross-linked high-performance compounds – for use in Aerospace, Alternative Energy, Automotive, Healthcare, Membranes, Oil and Gas, Packaging, Plumbing, Semiconductors, Wire and Cable, and other industries. Learn more atwww.solvay.com.

As an international chemical group, SOLVAY assists industries in finding and implementing ever more responsible and value-creating solutions. Solvay generates 90% of its net sales in activities where it is among the world's top three players. It serves many markets, varying from energy and the environment to automotive and aerospace or electricity and electronics, with one goal: to raise the performance of its clients and improve society's quality of life. The group is headquartered in Brussels, employs about 29,400 people in 56 countries and generated 9.9 billion euros in net sales in 2013. Solvay SA is listed as SOLB.BE on NYSE Euronext in Brussels and Paris (Bloomberg: SOLB:BB - Reuters: SOLB.BR).